You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSotalol
Accession NumberDB00489  (APRD01230)
TypeSmall Molecule
GroupsApproved
Description

An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]

Structure
Thumb
Synonyms
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
beta-Cardone
Sotalol
Sotalolo
Sotalolum
External Identifiers
  • MJ 1999
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-sotaloltablet160 mgoralAvanstra Inc2011-08-112014-08-21Canada
Ava-sotaloltablet80 mgoralAvanstra Inc2011-08-112014-08-21Canada
Betapacetablet120 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapacetablet160 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapacetablet80 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapace AFtablet120 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFtablet160 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFtablet80 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Co Sotaloltablet160 mgoralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Co Sotaloltablet80 mgoralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Dom-sotaloltablet160 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-sotaloltablet80 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Ftp-sotaloltablet160 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-sotaloltablet80 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Gen-sotalol 240mgtablet240 mgoralGenpharm Ulc1996-10-212009-08-05Canada
Jamp-sotaloltablet160 mgoralJamp Pharma Corporation2011-10-20Not applicableCanada
Jamp-sotaloltablet80 mgoralJamp Pharma Corporation2011-10-20Not applicableCanada
Linsotalol - Tab 80mgtablet80 mgoralLinson Pharma Co.1995-12-312006-05-29Canada
Linsotalol -tab 160mgtablet160 mgoralLinson Pharma Co.1995-12-312006-05-29Canada
Med Sotaloltablet160 mgoralMedican Pharma Incorporated1998-02-052011-03-29Canada
Med Sotaloltablet80 mgoralMedican Pharma Incorporated1998-02-052011-03-29Canada
Mylan-sotaloltablet160 mgoralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Mylan-sotaloltablet80 mgoralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Novo-sotalol Tab 160mgtablet160 mgoralNovopharm Limited1997-05-132015-10-26Canada
Novo-sotalol Tab 80mgtablet80 mgoralNovopharm Limited1997-05-132015-10-26Canada
Nu-sotalol - Tab 160 mgtablet160 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-sotalol - Tab 80mgtablet80 mgoralNu Pharm Inc1996-12-312012-09-04Canada
PHL-sotaloltablet80 mgoralPharmel Inc1998-12-01Not applicableCanada
PHL-sotaloltablet160 mgoralPharmel Inc1998-12-01Not applicableCanada
PMS-sotalol - 160 mgtablet160 mgoralPharmascience Inc1998-07-22Not applicableCanada
PMS-sotalol - 240 mgtablet240 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-sotalol - 80 mgtablet80 mgoralPharmascience Inc1998-07-22Not applicableCanada
Pro-sotaloltablet80 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Pro-sotaloltablet160 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Ratio-sotaloltablet160 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Ratio-sotaloltablet80 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Rho-sotaloltablet240 mgoralRhoxalpharma IncNot applicableNot applicableCanada
Rhoxal-sotaloltablet160 mgoralRhoxalpharma Inc1997-12-022009-11-24Canada
Rhoxal-sotaloltablet80 mgoralRhoxalpharma Inc1997-12-022009-11-24Canada
Riva-sotaloltablet160 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-sotaloltablet80 mgoralLaboratoire Riva Inc2010-06-04Not applicableCanada
Riva-sotaloltablet160 mgoralLaboratoire Riva Inc2000-05-23Not applicableCanada
Riva-sotaloltablet80 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Rylosoltablet240 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Rylosoltablet160 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Rylosoltablet80 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Sandoz Sotaloltablet160 mgoralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sandoz Sotaloltablet80 mgoralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sotacor Tab 160mgtablet160 mgoralBristol Labs Division Of Bristol Myers Squibb1985-12-312005-08-01Canada
Sotacor Tab 240mgtablet240 mgoralBristol Labs Division Of Bristol Myers Squibb1993-12-311996-09-09Canada
Sotacor Tab 80mgtablet80 mgoralBristol Labs Division Of Bristol Myers Squibb1993-12-312005-08-01Canada
Sotaloltablet160 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Sotaloltablet80 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Sotaloltablet160 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Sotaloltablet80 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Sotalol Hydrochlorideinjection15 mg/mLintravenousAltathera Pharmaceuticals, Llc2015-10-15Not applicableUs
Sotalol Hydrochlorideinjection15 mg/mLintravenousMylan Institutional LLC2009-09-30Not applicableUs
Sotalol-160 - Tab 160mgtablet160 mgoralPro Doc Limitee1997-01-152009-07-23Canada
Sotalol-80 - Tab 80mgtablet80 mgoralPro Doc Limitee1997-01-152010-07-13Canada
Sotamoltablet80 mgoralTechnilab Pharma Inc.1998-10-292006-07-28Canada
Sotamoltablet160 mgoralTechnilab Pharma Inc.1998-10-292006-07-28Canada
Sotylizesolution5 mg/mLoralArbor Pharmaceuticals, Inc.2015-03-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sotalol - Tab 160mgtablet160 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-sotalol 80mg Tabletstablet80 mgoralApotex Inc1996-12-31Not applicableCanada
Sorinetablet240 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet160 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet120 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet80 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet80 mg/1oralCardinal Health2011-02-15Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralProficient Rx LP2003-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralPhysicians Total Care, Inc.2000-12-04Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralRebel Distributors Corp2000-05-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralPhysicians Total Care, Inc.2006-03-14Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAidarex Pharmaceuticals LLC2003-02-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-02-01Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralPd Rx Pharmaceuticals, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAmerican Health Packaging2013-06-122016-01-01Us
Sotalol Hydrochloridetablet120 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralCarilion Materials Management2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAmerican Health Packaging2014-03-18Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralPhysicians Total Care, Inc.2009-04-08Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralTeva Pharmaceuticals USA Inc2000-05-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BiosotalSanofi-Aventis
CardolAlphapharm
DarobAbbott
Darob miteAbbott
HipecorMerck
LoritmikKrka
RytmobetaAbbott
SotacorBristol-Myers Squibb
SotagardGlaxoSmithKline
SotalexBristol-Myers Squibb
SotaporBristol-Myers Squibb
TalozinAdeka
Tan ShiChia Tai Tianqing
Xi An LinChangzhou Pharmaceutical Factory
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sotalol Hydrochloride
959-24-0
Thumb
  • InChI Key: VIDRYROWYFWGSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 308.096140945
  • Average Mass: 308.825
DBSALT000318
Categories
UNIIA6D97U294I
CAS number3930-20-9
WeightAverage: 272.364
Monoisotopic: 272.119463206
Chemical FormulaC12H20N2O3S
InChI KeyInChIKey=ZBMZVLHSJCTVON-UHFFFAOYSA-N
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
IUPAC Name
N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
SMILES
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Aralkylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.
PharmacodynamicsSotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.
Mechanism of actionSotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.
Related Articles
AbsorptionIn healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.
Volume of distributionNot Available
Protein bindingSotalol does not bind to plasma proteins.
Metabolism

Sotalol is not metabolized.

Route of eliminationExcretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.
Half lifeMean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.
ClearanceNot Available
ToxicityThe most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sotalol Action PathwayDrug actionSMP00660
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6708
P-glycoprotein inhibitor INon-inhibitor0.8881
P-glycoprotein inhibitor IINon-inhibitor0.9638
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7392
CYP450 2D6 substrateNon-substrate0.8296
CYP450 3A4 substrateNon-substrate0.6194
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8276
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.587
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2873 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.846
hERG inhibition (predictor II)Non-inhibitor0.8701
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Academic pharmaceuticals inc
  • Bayer healthcare pharmaceuticals inc
  • Upsher smith laboratories inc
  • Amneal pharmaceutical
  • Apotex inc
  • Apotex inc etobicoke site
  • Impax pharmaceuticals
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral160 mg
Tabletoral80 mg
Tabletoral240 mg
Injectionintravenous15 mg/mL
Tabletoral120 mg/1
Tabletoral160 mg/1
Tabletoral240 mg/1
Tabletoral80 mg/1
Solutionoral5 mg/mL
Prices
Unit descriptionCostUnit
Betapace AF 100 160 mg tablet Box538.2USD box
Betapace AF 60 120 mg tablet Bottle311.06USD bottle
Betapace 240 mg tablet8.94USD tablet
Sotalol hcl 150 mg/10 ml vial7.8USD ml
Betapace 160 mg tablet6.87USD tablet
Betapace af 160 mg tablet6.24USD tablet
Sorine 240 mg tablet5.6USD tablet
Betapace 120 mg tablet5.5USD tablet
Sotalol HCl 240 mg tablet5.29USD tablet
Sotalol 240 mg tablet5.09USD tablet
Betapace af 120 mg tablet4.99USD tablet
Sotalol HCl (AF) 160 mg tablet4.45USD tablet
Sorine 160 mg tablet4.31USD tablet
Sotalol af 160 mg tablet4.27USD tablet
Betapace 80 mg tablet4.12USD tablet
Sotalol HCl 160 mg tablet4.07USD tablet
Sotalol 160 mg tablet3.92USD tablet
Betapace af 80 mg tablet3.74USD tablet
Sotalol HCl (AF) 120 mg tablet3.56USD tablet
Sorine 120 mg tablet3.46USD tablet
Sotalol af 120 mg tablet3.42USD tablet
Sotalol HCl 120 mg tablet3.26USD tablet
Sotalol 120 mg tablet3.13USD tablet
Sotalol HCl 80 mg tablet2.67USD tablet
Sotalol HCl (AF) 80 mg tablet2.67USD tablet
Sorine 80 mg tablet2.61USD tablet
Sotalol af 80 mg tablet2.56USD tablet
Sotalol 80 mg tablet2.35USD tablet
Apo-Sotalol 160 mg Tablet0.68USD tablet
Co Sotalol 160 mg Tablet0.68USD tablet
Mylan-Sotalol 160 mg Tablet0.68USD tablet
Novo-Sotalol 160 mg Tablet0.68USD tablet
Nu-Sotalol 160 mg Tablet0.68USD tablet
Pms-Sotalol 160 mg Tablet0.68USD tablet
Ratio-Sotalol 160 mg Tablet0.68USD tablet
Sandoz Sotalol 160 mg Tablet0.68USD tablet
Apo-Sotalol 80 mg Tablet0.62USD tablet
Co Sotalol 80 mg Tablet0.62USD tablet
Mylan-Sotalol 80 mg Tablet0.62USD tablet
Novo-Sotalol 80 mg Tablet0.62USD tablet
Nu-Sotalol 80 mg Tablet0.62USD tablet
Pms-Sotalol 80 mg Tablet0.62USD tablet
Ratio-Sotalol 80 mg Tablet0.62USD tablet
Sandoz Sotalol 80 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206.5-207 °CPhysProp
water solubilitySoluble (5510 mg/L)Not Available
logP0.24BURGOT,G ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.782 mg/mLALOGPS
logP0.85ALOGPS
logP-0.4ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.12 m3·mol-1ChemAxon
Polarizability29.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7-12. [PubMed:8691967 ]
External Links
ATC CodesC07AA07C07AA57C07BA07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (93.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcepromazineAcepromazine may increase the hypotensive activities of Sotalol.
AcetylcholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetylcholine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.
AlfuzosinSotalol may increase the orthostatic hypotensive activities of Alfuzosin.
Aluminum hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.
AmifostineSotalol may increase the hypotensive activities of Amifostine.
BretyliumBretylium may increase the bradycardic activities of Sotalol.
BrimonidineBrimonidine may increase the antihypertensive activities of Sotalol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.
ButabarbitalThe serum concentration of Sotalol can be decreased when it is combined with Butabarbital.
ButethalThe serum concentration of Sotalol can be decreased when it is combined with Butethal.
CabergolineSotalol may increase the vasoconstricting activities of Cabergoline.
Calcium carbonateThe serum concentration of Sotalol can be decreased when it is combined with Calcium carbonate.
CarbacholThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbachol.
CeritinibSotalol may increase the bradycardic activities of Ceritinib.
ChlorpropamideSotalol may increase the hypoglycemic activities of Chlorpropamide.
CitalopramCitalopram may increase the QTc-prolonging activities of Sotalol.
DiazoxideDiazoxide may increase the hypotensive activities of Sotalol.
DigoxinSotalol may increase the bradycardic activities of Digoxin.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Sotalol.
DipyridamoleDipyridamole may increase the bradycardic activities of Sotalol.
DofetilideDofetilide may increase the QTc-prolonging activities of Sotalol.
DuloxetineSotalol may increase the orthostatic hypotensive activities of Duloxetine.
EsmololEsmolol may increase the bradycardic activities of Sotalol.
FingolimodFingolimod may increase the arrhythmogenic activities of Sotalol.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sotalol.
GoserelinGoserelin may increase the QTc-prolonging activities of Sotalol.
HeptabarbitalThe serum concentration of Sotalol can be decreased when it is combined with Heptabarbital.
HexobarbitalThe serum concentration of Sotalol can be decreased when it is combined with Hexobarbital.
InfliximabInfliximab may decrease the antihypertensive activities of Sotalol.
IvabradineIvabradine may increase the QTc-prolonging activities of Sotalol.
LacosamideSotalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sotalol.
LevodopaSotalol may increase the orthostatic hypotensive activities of Levodopa.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Sotalol.
Magnesium hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.
MethacholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Methacholine.
MethohexitalThe serum concentration of Sotalol can be decreased when it is combined with Methohexital.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Sotalol.
MidodrineSotalol may increase the bradycardic activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Sotalol.
MolsidomineMolsidomine may increase the hypotensive activities of Sotalol.
MoxonidineMoxonidine may increase the hypotensive activities of Sotalol.
NicorandilNicorandil may increase the hypotensive activities of Sotalol.
NifedipineNifedipine may increase the hypotensive activities of Sotalol.
ObinutuzumabSotalol may increase the hypotensive activities of Obinutuzumab.
OctreotideOctreotide may increase the bradycardic activities of Sotalol.
OrciprenalineSotalol may decrease the activities of Orciprenaline.
PentobarbitalThe serum concentration of Sotalol can be decreased when it is combined with Pentobarbital.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Sotalol.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Sotalol.
PrazosinSotalol may increase the orthostatic hypotensive activities of Prazosin.
PrimidoneThe serum concentration of Sotalol can be decreased when it is combined with Primidone.
PropafenonePropafenone may increase the arrhythmogenic activities of Sotalol.
QuinineQuinine may increase the hypotensive activities of Sotalol.
RegorafenibRegorafenib may increase the bradycardic activities of Sotalol.
ReserpineReserpine may increase the hypotensive activities of Sotalol.
RituximabSotalol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Sotalol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Sotalol.
SecobarbitalThe serum concentration of Sotalol can be decreased when it is combined with Secobarbital.
Sodium bicarbonateThe serum concentration of Sotalol can be decreased when it is combined with Sodium bicarbonate.
SufentanilSufentanil may increase the bradycardic activities of Sotalol.
TacrineTacrine may increase the bradycardic activities of Sotalol.
TadalafilTadalafil may increase the antihypertensive activities of Sotalol.
TheophyllineSotalol may decrease the activities of Theophylline.
TofacitinibTofacitinib may increase the bradycardic activities of Sotalol.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Sotalol.
TreprostinilTreprostinil may increase the hypotensive activities of Sotalol.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.
VardenafilVardenafil may increase the antihypertensive activities of Sotalol.
YohimbineYohimbine may decrease the antihypertensive activities of Sotalol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000 Aug 8;102(6):706-12. [PubMed:10931813 ]
  2. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res. 2000 Nov 24;87(11):1012-8. [PubMed:11090546 ]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388 ]
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. [PubMed:16076272 ]
  5. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. [PubMed:16686685 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 21, 2014 12:54